MLTX (MoonLake Immunotherapeutics AG) Net Profit

Official company branding of MoonLake Immunotherapeutics AG (MLTX)

Developing immune drugs involves immense scientific risks and pressure from industry behemoths. MoonLake Immunotherapeutics (MLTX) net income shows a turning point driven by the implementation of AI to accelerate molecular modeling amid the planned burn of cash reserves due to a lack of sales. The value of -0.26 reflects the latest metric value, capturing the issuer's current financial stability.

MLTX (MoonLake Immunotherapeutics) Company Net Income history from 04/28/2023 to 11/01/2026

Comprehensive metric breakdowns and analytics for MoonLake (MLTX)

- price and consensus price forecast:
Stock Quotes MoonLake Corp|MLTX - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization MoonLake Corp|MLTX - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share MoonLake Immunotherapeutics|MLTX - Company Book Value|Market Cap to Net Assets Ratio moonlaketx.com|MLTX - Company Total Assets
- debt and solvency information:
Debt to Capital MoonLake Immunotherapeutics|MLTX - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio MoonLake Immunotherapeutics AG|MLTX - Company Aggregate Debts|Debts to Book Capitalization MoonLake Corp|MLTX - Company Long-Term Debts|Company Short-Term Debt MoonLake Immunotherapeutics|Immediate Liquidity moonlaketx.com
- net income and valuation multiples indicators:
MLTX - Company Net Income
Fundamental valuation:MoonLake Immunotherapeutics
Signature product of moonlaketx.com

MoonLake Immunotherapeutics (MLTX) profit represents the final financial result reflecting the business's ability to generate net income after deducting all operating and tax obligations. By analyzing the MoonLake Immunotherapeutics (MLTX) profit chart, an investor can see the capitalization dynamics of MLTX, which currently depends critically on investments in the development of antibodies for the therapy of psoriasis and pyoderma gangrenosum until the drugs reach commercialization.

Direct competitors

Net Income Ascendis|MDGL (Madrigal Pharmaceuticals) - Net Profit|Net Profit corcept.com|Net Income RYTM (Rhythm Pharmaceuticals, Inc.)|AKRO (Akero Therapeutics, Inc.) - Final Profit|Company Net Income Metsera Corp MTSR|CRNX - Net Income|NewAmsterdam Pharma - Net Profit|Company Net Income soleno.life|FOLD (Amicus Therapeutics, Inc.) - Net Income|ETNB: Profit After Payment of Taxes|AGIO (Agios Pharmaceuticals Inc) - Net Profit|Net Profit Structure Corp|Net Profit MDXG|Company Net Income RZLT (rezolutebio.com)|Company Net Income Lexicon Pharmaceuticals, Inc. LXRX|MBX Biosciences, Inc. (MBX) - Company Net Income|ALT - Company Net Income|AARD: Company Net Income|SGMT: Net Profit|BIOA - Net Financial Result|Company Net Income Biomea Fusion|Quince (QNCX) - Net Financial Result|Company Net Income Fractyl (GUTS)|Net Income vtvtherapeutics.com VTVT|Company Net Income Agape ATP ATPC|PLUR - Net Income|SYBX - Company Net Income|Company Net Income Lipocine Inc|matinasbiopharma.com (MTNB) - Company Net Income|Company Net Income Spruce Biosciences Inc. (SPRB)|Company Net Income Galecto, Inc.|Company Profit CTCX (carmellrx.com)|Company Net Income Lumos Pharma (LUMO)|Company Net Income ONVO (Organovo Holdings)|Net Profit RDUS (Radius Health)